Saturday, 3 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 6, 2026

Sezzle and Sea have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
Sezzle and Sea have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – March 6, 2026 – Zacks Equity Research shares Sezzle SEZL as the Bull of the Day and Sea Ltd…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Zacks Consensus Estimate for American Express' 2026 earnings is pegged at $17.50 per share, implying a 13.8% jump from the year-ago period

    80% confidence

  • Adjusted EBITDA at least flat year over year for 2026

    80% confidence

  • Sezzle is a Zack Rank #1 (Strong Buy)

    80% confidence

  • Garena is guiding to double digit bookings growth in 2026

    80% confidence

  • Projecting revenue growth of 25 to 30% year over year for FY26

    80% confidence

  • Guiding to $4.70 in EPS versus $4.33 expected for FY26

    80% confidence

  • B. Riley Securities reiterated their 'Buy' rating on Sezzle

    80% confidence

  • Management emphasized a focus on higher lifetime value subscribers and proprietary shopping features, positioning the company to sustain earnings quality into 2026

    80% confidence

  • Sea Ltd. is a Zacks Rank #5 (Strong Sell)

    80% confidence

  • Guiding to roughly 25% GMV growth at Shopee for 2026

    80% confidence

  • Guiding to $170 million in adjusted net income, up 31% year over year on a per share basis for FY26

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com